Vaporized medicants and methods of use
Inventors
Chong, Alexander ChinHak • Bartkowski, William P • Thompson, Marshall A
Assignees
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Publication Number
US-10918684-B2
Publication Date
2021-02-16
Expiration Date
Abstract
A method and formulation for delivering a PDE-5 inhibitor in a vaporized state using low temperatures to vaporize the formulation. The formulation contains an inert non-reactive compound that lowers the heat of vaporization of the formulation, and the PDE-5 inhibitor. The formulation may optionally contain glycerin, alcohol, and/or water. Examples of inert non-reactive compounds that can sufficiently lower the heat of vaporization of the formulation include propylene glycol, vegetable glycerin and polysorbate. The formulation can be vaporized using a hand-held low temperature vaporizer or atomizer.
Core Innovation
The invention relates to delivering medicants through inhalation by acquiring a medicant solution suitable for vaporization and vaporizing the medicant solution to provide an effective serving of the medicant for inhalation. The medicant solution includes an excipient and a medicant, where the medicant is a phosphodiesterase type 5 inhibitor.
In one aspect, the medicant solution comprises excipients including propylene glycol, vegetable glycerin, water, and alcohol present in defined approximate percentage ranges, and the medicant solution is vaporized at a temperature ranging from approximately 90 degrees C. to approximately 385 degrees C. using a vaporizer such that an effective serving is provided to a user for inhalation.
In another aspect, the medicant solution comprises an inert non-reactive compound excipient and a phosphodiesterase type 5 inhibitor, where the medicant solution is vaporized using a low temperature vaporizer at a temperature ranging from approximately 90 degrees C. to approximately 120 degrees C. within 2 minutes of activation. In a further aspect, the inert non-reactive compound is propylene glycol, and the medicant solution is vaporized at a temperature ranging from approximately 170 degrees C. to approximately 200 degrees C. within 2 minutes of activation using a low temperature vaporizer.
Claims Coverage
The independent claims are directed to inhalation delivery methods that vaporize a medicant solution containing a phosphodiesterase type 5 inhibitor using specified excipients and defined temperature ranges, including constraints tied to low temperature vaporization and timing within 2 minutes of activation. Across the independent claims, the coverage includes three main inventive feature groupings.
Vaporized medicant solution for inhalation with PDE-5 inhibitor and specific excipient mixture
Acquiring a medicant solution suitable for vaporization comprising an excipient comprising propylene glycol, vegetable glycerin, water, and alcohol in defined approximate percentage ranges, and a phosphodiesterase type 5 inhibitor, and vaporizing the medicant solution at a temperature ranging from approximately 90 degrees C. to approximately 385 degrees C. using a vaporizer such that an effective serving is provided for inhalation.
Low temperature vaporization within 2 minutes using polysorbate excipient and PDE-5 inhibitor
Acquiring a medicant solution suitable for vaporization comprising an excipient comprising an inert non-reactive compound and a phosphodiesterase type 5 inhibitor, and vaporizing the medicant solution at a temperature ranging from approximately 90 degrees C. to approximately 120 degrees C. within 2 minutes of activation using a low temperature vaporizer, such that an effective serving of the phosphodiesterase type 5 inhibitor is provided for inhalation, wherein the inert non-reactive compound is polysorbate.
Low temperature vaporization within 2 minutes using propylene glycol excipient and PDE-5 inhibitor
Acquiring a medicant solution suitable for vaporization comprising an excipient comprising an inert non-reactive compound and a phosphodiesterase type 5 inhibitor, and vaporizing the medicant solution at a temperature ranging from approximately 170 degrees C. to approximately 200 degrees C. within 2 minutes of activation using a low temperature vaporizer, such that an effective serving of the phosphodiesterase type 5 inhibitor is provided for inhalation, wherein the inert non-reactive compound is propylene glycol.
The independent claims collectively cover inhalation delivery methods that provide an effective serving of a phosphodiesterase type 5 inhibitor by vaporizing a medicant solution. The methods are constrained by excipient identity and composition, by vaporization temperature ranges, and by low temperature vaporization within 2 minutes of activation for the polysorbate and propylene glycol embodiments.
Stated Advantages
Provides an effective serving of the medicant solution or the phosphodiesterase type 5 inhibitor to a user for inhalation.
Documented Applications
Inhalation delivery of medicants, including medicants using phosphodiesterase type 5 inhibitors as sexual aids via PDE-5 inhibitors.
Interested in licensing this patent?